Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 28 entries
Sorted by: Best Match Show Resources per page
High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab).

Biochemistry and biophysics reports

Crivianu-Gaita V, Romaschin A, Thompson M.
PMID: 29124142
Biochem Biophys Rep. 2015 Apr 25;2:23-28. doi: 10.1016/j.bbrep.2015.04.004. eCollection 2015 Jul.

Antibodies have widespread applications in areas ranging from therapeutics to chromatography and protein microarrays. Certain applications require only the fragment antigen-binding (Fab) units of the protein. This study compares the cleavage efficacy of dithiothreitol (DTT), mercaptoethylamine (MEA), and dithiobutylamine...

Cite
Crivianu-Gaita V, Romaschin A, Thompson M. High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab). Biochem Biophys Rep. 2015;2:23-28doi: 10.1016/j.bbrep.2015.04.004.
Crivianu-Gaita, V., Romaschin, A., & Thompson, M. (2015). High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab). Biochemistry and biophysics reports, 223-28. https://doi.org/10.1016/j.bbrep.2015.04.004
Crivianu-Gaita, Victor, et al. "High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab)." Biochemistry and biophysics reports vol. 2 (2015): 23-28. doi: https://doi.org/10.1016/j.bbrep.2015.04.004
Crivianu-Gaita V, Romaschin A, Thompson M. High efficiency reduction capability for the formation of Fab׳ antibody fragments from F(ab). Biochem Biophys Rep. 2015 Apr 25;2:23-28. doi: 10.1016/j.bbrep.2015.04.004. eCollection 2015 Jul. PMID: 29124142; PMCID: PMC5668623.
Copy Download .nbib Format: NLM
Introduction to Immunohistochemistry: From to Evolving Science to Timeless Art.

Methods in molecular biology (Clifton, N.J.)

Del Valle L.
PMID: 34859395
Methods Mol Biol. 2022;2422:1-16. doi: 10.1007/978-1-0716-1948-3_1.

Immunohistochemistry and all techniques that use antibodies and fluorescence are widespread, essential and irreplaceable tools used in both research laboratory settings and diagnostic pathology laboratories. The field was born approximately 80 years ago, with the idea that antibodies could...

Cite
Del Valle L. Introduction to Immunohistochemistry: From to Evolving Science to Timeless Art. Methods Mol Biol. 2022;2422:1-16doi: 10.1007/978-1-0716-1948-3_1.
Del Valle, L. (2022). Introduction to Immunohistochemistry: From to Evolving Science to Timeless Art. Methods in molecular biology (Clifton, N.J.), 24221-16. https://doi.org/10.1007/978-1-0716-1948-3_1
Del Valle, Luis. "Introduction to Immunohistochemistry: From to Evolving Science to Timeless Art." Methods in molecular biology (Clifton, N.J.) vol. 2422 (2022): 1-16. doi: https://doi.org/10.1007/978-1-0716-1948-3_1
Del Valle L. Introduction to Immunohistochemistry: From to Evolving Science to Timeless Art. Methods Mol Biol. 2022;2422:1-16. doi: 10.1007/978-1-0716-1948-3_1. PMID: 34859395.
Copy Download .nbib Format: NLM
Alpha-Klotho, a critical protein for lung health, is not expressed in normal lung.

FASEB bioAdvances

Zhang J, Cao K, Pastor JV, Li L, Moe OW, Hsia CCW.
PMID: 32123814
FASEB Bioadv. 2019 Oct 29;1(11):675-687. doi: 10.1096/fba.2019-00016. eCollection 2019 Nov.

Alpha-Klotho (αKlotho), produced by the kidney and selected organs, is essential for tissue maintenance and protection. Homozygous αKlotho-deficiency leads to premature multi-organ degeneration and death; heterozygous insufficiency leads to apoptosis, oxidative stress, and increased injury susceptibility. There is inconsistent...

Cite
Zhang J, Cao K, Pastor JV, et al. Alpha-Klotho, a critical protein for lung health, is not expressed in normal lung. FASEB Bioadv. 2019;1(11):675-687doi: 10.1096/fba.2019-00016.
Zhang, J., Cao, K., Pastor, J. V., Li, L., Moe, O. W., & Hsia, C. C. W. (2019). Alpha-Klotho, a critical protein for lung health, is not expressed in normal lung. FASEB bioAdvances, 1(11), 675-687. https://doi.org/10.1096/fba.2019-00016
Zhang, Jianning, et al. "Alpha-Klotho, a critical protein for lung health, is not expressed in normal lung." FASEB bioAdvances vol. 1,11 (2019): 675-687. doi: https://doi.org/10.1096/fba.2019-00016
Zhang J, Cao K, Pastor JV, Li L, Moe OW, Hsia CCW. Alpha-Klotho, a critical protein for lung health, is not expressed in normal lung. FASEB Bioadv. 2019 Oct 29;1(11):675-687. doi: 10.1096/fba.2019-00016. eCollection 2019 Nov. PMID: 32123814; PMCID: PMC6996373.
Copy Download .nbib Format: NLM
Management of severe hidradenitis suppurativa with biologic therapy and wide excision.

Archives of plastic surgery

Lim SYD, Cheong EC, Oon HH.
PMID: 31006182
Arch Plast Surg. 2019 May;46(3):272-276. doi: 10.5999/aps.2018.00339. Epub 2019 Apr 20.

Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the...

Cite
Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Arch Plast Surg. 2019;46(3):272-276doi: 10.5999/aps.2018.00339.
Lim, S. Y. D., Cheong, E. C., & Oon, H. H. (2019). Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Archives of plastic surgery, 46(3), 272-276. https://doi.org/10.5999/aps.2018.00339
Lim, Shi Yu Derek, et al. "Management of severe hidradenitis suppurativa with biologic therapy and wide excision." Archives of plastic surgery vol. 46,3 (2019): 272-276. doi: https://doi.org/10.5999/aps.2018.00339
Lim SYD, Cheong EC, Oon HH. Management of severe hidradenitis suppurativa with biologic therapy and wide excision. Arch Plast Surg. 2019 May;46(3):272-276. doi: 10.5999/aps.2018.00339. Epub 2019 Apr 20. PMID: 31006182; PMCID: PMC6536865.
Copy Download .nbib Format: NLM
Immunotherapy for B-cell lymphoma: current status and prospective advances.

Frontiers in immunology

Hollander N.
PMID: 22566889
Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012.

Therapy for non-Hodgkin's lymphoma has progressed significantly over the last decades. However, the majority of patients remain incurable, and novel therapies are needed. Because immunotherapy ideally offers target selectivity, an ever increasing number of immunotherapies, both passive and active,...

Cite
Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol. 2012;3:3doi: 10.3389/fimmu.2012.00003.
Hollander, N. (2012). Immunotherapy for B-cell lymphoma: current status and prospective advances. Frontiers in immunology, 33. https://doi.org/10.3389/fimmu.2012.00003
Hollander, Nurit. "Immunotherapy for B-cell lymphoma: current status and prospective advances." Frontiers in immunology vol. 3 (2012): 3. doi: https://doi.org/10.3389/fimmu.2012.00003
Hollander N. Immunotherapy for B-cell lymphoma: current status and prospective advances. Front Immunol. 2012 Jan 24;3:3. doi: 10.3389/fimmu.2012.00003. eCollection 2012. PMID: 22566889; PMCID: PMC3342070.
Copy Download .nbib Format: NLM
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.

Journal of thrombosis and haemostasis : JTH

Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M, Bloomfield D.
PMID: 34714969
J Thromb Haemost. 2021 Oct 29; doi: 10.1111/jth.15577. Epub 2021 Oct 29.

BACKGROUND: Factor XI (FXI) inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the...

Cite
Yi BA, Freedholm D, Widener N, et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2021;doi: 10.1111/jth.15577.
Yi, B. A., Freedholm, D., Widener, N., Wang, X., Simard, E., Cullen, C., Al-Saady, N. M., Lepor, N. E., Coulter, S., Lovern, M., & Bloomfield, D. (2021). Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.15577
Yi, B Alexander, et al. "Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa." Journal of thrombosis and haemostasis : JTH vol. (2021). doi: https://doi.org/10.1111/jth.15577
Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M, Bloomfield D. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2021 Oct 29; doi: 10.1111/jth.15577. Epub 2021 Oct 29. PMID: 34714969.
Copy Download .nbib Format: NLM
Expression and analysis of McAbs antigen against human hepatocellular carcinoma.

World journal of gastroenterology

Mi L, Chen ZN.
PMID: 27041961
World J Gastroenterol. 1997 Jun 15;3(2):110. doi: 10.3748/wjg.v3.i2.110.

AIM: To analyze the cause of tumor antigen heterogeneity and solve the problem of targeting diagnosis and therapy.METHODS: Using flow cytometry, the expression of McAbs antigen against human hepatocellular carcinoma (HAb18, E5, F11 and HAb27) was investigated. Analyses of...

Cite
Mi L, Chen ZN. Expression and analysis of McAbs antigen against human hepatocellular carcinoma. World J Gastroenterol. 1997;3(2):110doi: 10.3748/wjg.v3.i2.110.
Mi, L., & Chen, Z. N. (1997). Expression and analysis of McAbs antigen against human hepatocellular carcinoma. World journal of gastroenterology, 3(2), 110. https://doi.org/10.3748/wjg.v3.i2.110
Mi, L, and Chen, Z N. "Expression and analysis of McAbs antigen against human hepatocellular carcinoma." World journal of gastroenterology vol. 3,2 (1997): 110. doi: https://doi.org/10.3748/wjg.v3.i2.110
Mi L, Chen ZN. Expression and analysis of McAbs antigen against human hepatocellular carcinoma. World J Gastroenterol. 1997 Jun 15;3(2):110. doi: 10.3748/wjg.v3.i2.110. PMID: 27041961; PMCID: PMC4801909.
Copy Download .nbib Format: NLM
Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5.

Journal of cell communication and signaling

Wei L, McKeon F, Russo JW, Lemire J, Castellot J.
PMID: 19401828
J Cell Commun Signal. 2009 Mar;3(1):65-77. doi: 10.1007/s12079-009-0054-6. Epub 2009 Apr 29.

The CCN family of proteins typically consists of four distinct peptide domains: an insulin-like growth factor binding protein-type (IGFBP) domain, a Von Willebrand Factor C (VWC) domain, a thrombospondin type 1 repeat (TSP1) domain, and a carboxy-terminal (CT) domain....

Cite
Wei L, McKeon F, Russo JW, et al. Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5. J Cell Commun Signal. 2009;3(1):65-77doi: 10.1007/s12079-009-0054-6.
Wei, L., McKeon, F., Russo, J. W., Lemire, J., & Castellot, J. (2009). Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5. Journal of cell communication and signaling, 3(1), 65-77. https://doi.org/10.1007/s12079-009-0054-6
Wei, Lan, et al. "Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5." Journal of cell communication and signaling vol. 3,1 (2009): 65-77. doi: https://doi.org/10.1007/s12079-009-0054-6
Wei L, McKeon F, Russo JW, Lemire J, Castellot J. Domain-and species-specific monoclonal antibodies recognize the Von Willebrand Factor-C domain of CCN5. J Cell Commun Signal. 2009 Mar;3(1):65-77. doi: 10.1007/s12079-009-0054-6. Epub 2009 Apr 29. PMID: 19401828; PMCID: PMC2686757.
Copy Download .nbib Format: NLM
A method to detect McLeod phenotype red blood cells.

Immunohematology

Øyen R, Reid ME, Rubinstein P, Ralph H.
PMID: 15387728
Immunohematology. 1996;12(4):160-3.

It is important to identify the McLeod phenotype in order to differentiate the McLeod syndrome from other causes of acanthocytosis, e.g., chorea acanthocytosis. A proportion of males with the McLeod phenotype have X-linked chronic granulomatous disease. Because anti-Kx +...

Cite
Øyen R, Reid ME, Rubinstein P, et al. A method to detect McLeod phenotype red blood cells. Immunohematology. 1996;12(4):160-3
Øyen, R., Reid, M. E., Rubinstein, P., & Ralph, H. (1996). A method to detect McLeod phenotype red blood cells. Immunohematology, 12(4), 160-3.
Øyen, R, et al. "A method to detect McLeod phenotype red blood cells." Immunohematology vol. 12,4 (1996): 160-3.
Øyen R, Reid ME, Rubinstein P, Ralph H. A method to detect McLeod phenotype red blood cells. Immunohematology. 1996;12(4):160-3. PMID: 15387728.
Copy Download .nbib Format: NLM
[CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?].

Schmerz (Berlin, Germany)

Hamann T, Rimmele F, Jürgens TP.
PMID: 35041064
Schmerz. 2022 Jan 18; doi: 10.1007/s00482-021-00613-x. Epub 2022 Jan 18.

Migraine is associated with a high individual level of suffering. Therefore, an effective preventive treatment is highly important. The spectrum of classical prophylactic drugs has now been expanded to include monoclonal antibodies against calcitonin gene-related peptide (CGRP) and its...

Cite
Hamann T, Rimmele F, Jürgens TP. CGRP-Antikörper in der Migräneprophylaxe : Der neue Standard in der Migränetherapie? [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]. Schmerz. 2022;doi: 10.1007/s00482-021-00613-x.
Hamann, T., Rimmele, F., & Jürgens, T. P. (2022). CGRP-Antikörper in der Migräneprophylaxe : Der neue Standard in der Migränetherapie? [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]. Schmerz (Berlin, Germany), . https://doi.org/10.1007/s00482-021-00613-x
Hamann, Till, et al. "CGRP-Antikörper in der Migräneprophylaxe : Der neue Standard in der Migränetherapie?" [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]. Schmerz (Berlin, Germany) vol. (2022). doi: https://doi.org/10.1007/s00482-021-00613-x
Hamann T, Rimmele F, Jürgens TP. CGRP-Antikörper in der Migräneprophylaxe : Der neue Standard in der Migränetherapie? [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]. Schmerz. 2022 Jan 18; doi: 10.1007/s00482-021-00613-x. Epub 2022 Jan 18. German. PMID: 35041064.
Copy Download .nbib Format: NLM
[Biologics in inflammatory bowel diseases].

Der Internist

Esters P, Hackenberg C, Schulze H, Dignass AU.
PMID: 35037947
Internist (Berl). 2022 Jan 17; doi: 10.1007/s00108-021-01255-y. Epub 2022 Jan 17.

BACKGROUND: In addition to conventional anti-inflammatory treatment for chronic inflammatory bowel disease (IBD), there has been an evolution of new treatment options over the past 20 years. Already approved biologics provide multiple treatment alternatives but also make the treatment...

Cite
Esters P, Hackenberg C, Schulze H, et al. Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Internist (Berl). 2022;doi: 10.1007/s00108-021-01255-y.
Esters, P., Hackenberg, C., Schulze, H., & Dignass, A. U. (2022). Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Der Internist, . https://doi.org/10.1007/s00108-021-01255-y
Esters, Philip, et al. "Biologika bei chronisch-entzündlichen Darmerkrankungen." [Biologics in inflammatory bowel diseases]. Der Internist vol. (2022). doi: https://doi.org/10.1007/s00108-021-01255-y
Esters P, Hackenberg C, Schulze H, Dignass AU. Biologika bei chronisch-entzündlichen Darmerkrankungen. [Biologics in inflammatory bowel diseases]. Internist (Berl). 2022 Jan 17; doi: 10.1007/s00108-021-01255-y. Epub 2022 Jan 17. German. PMID: 35037947.
Copy Download .nbib Format: NLM
Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa.

Journal of thrombosis and haemostasis : JTH

Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M, Bloomfield D.
PMID: 34714969
J Thromb Haemost. 2021 Oct 29; doi: 10.1111/jth.15577. Epub 2021 Oct 29.

BACKGROUND: Factor XI (FXI) inhibition offers the promise of hemostasis-sparing anticoagulation for the prevention and treatment of thromboembolic events. Abelacimab (MAA868) is a novel fully human monoclonal antibody that targets the catalytic domain and has dual activity against the...

Cite
Yi BA, Freedholm D, Widener N, et al. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2021;doi: 10.1111/jth.15577.
Yi, B. A., Freedholm, D., Widener, N., Wang, X., Simard, E., Cullen, C., Al-Saady, N. M., Lepor, N. E., Coulter, S., Lovern, M., & Bloomfield, D. (2021). Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. Journal of thrombosis and haemostasis : JTH, . https://doi.org/10.1111/jth.15577
Yi, Byungdoo Alexander, et al. "Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa." Journal of thrombosis and haemostasis : JTH vol. (2021). doi: https://doi.org/10.1111/jth.15577
Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, Al-Saady NM, Lepor NE, Coulter S, Lovern M, Bloomfield D. Pharmacokinetics and pharmacodynamics of Abelacimab (MAA868), a novel dual inhibitor of Factor XI and Factor XIa. J Thromb Haemost. 2021 Oct 29; doi: 10.1111/jth.15577. Epub 2021 Oct 29. PMID: 34714969.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 28 entries